<DOC>
	<DOCNO>NCT00150722</DOCNO>
	<brief_summary>It well known lower low-density lipoprotein ( LDL ) ( bad cholesterol ) beneficial decrease heart attack death . More recently , focus try raise HDL ( good ) cholesterol . The purpose present study determine addition sustain release preparation niacin ( Niaspan - medicine raise HDL cholesterol ) LDL lower statin type medication result improve vascular health . The study well one 's vessel wall ( endothelial function ) serve marker treatment effect study . Hypotheses : Extended-release ( ER ) niacin improve endothelial function measure brachial flow-mediated dilation ( FMD - 10 end-point ) pulse volume amplitude pulse arterial tonometry ( PAT ) ( 20 end-point ) subject establish atherosclerosis whose LDL cholesterol optimally treat statin therapy .</brief_summary>
	<brief_title>High-Density Lipoprotein ( HDL ) Modulation Endothelial Function</brief_title>
	<detailed_description>Purpose : To determine incremental value extended-release ( ER ) niacin combination high dose statin therapy brachial endothelial function subject coronary atherosclerosis . Hypotheses : 1 . ER niacin improve endothelial function measure brachial flow-mediated dilation ( FMD - primary end-point ) , hyperemic velocity pulse volume amplitude PAT ( 20 end-point ) subject establish atherosclerosis whose LDL cholesterol optimally treat statin therapy . 2 . Hyperemic pulse volume amplitude finger assess pulse arterial tonometry ( PAT ) correlate brachial FMD assess high resolution ultrasound brachial artery . Background : In patient establish coronary atherosclerosis , secondary prevention strategy lipid lower agent result event reduction 25-30 % . Despite aggressive cholesterol lower statin event rate remain 2-3 % per year subject high risk . While many new therapeutic target suggest , recently much interest modulation HDL cholesterol . Low HDL powerful risk factor coronary event . HDL function reverse cholesterol transport system remove excess cholesterol tissue include vessel wall . In addition , HDL vascular benefit include anti-oxidant direct endothelial effect . The effective available way modulate HDL niacin . An ER formulation niacin ( Niaspan - Kos ) available Canada 2005 show efficacious safe . The endothelium play key role vascular homeostasis release paracrine factor nitric oxide . Dysfunction endothelium occur response risk factor atherosclerosis . Endothelial function readily measure non-invasively human pharmacotherapy show reduce cardiovascular event improve endothelium-dependent vasodilation . In addition , recent study suggest measure endothelial function prognostic implication subject risk vascular event . As measurement endothelial function become well established surrogate marker disease activity utilized current study . The effect niacin endothelial function study . Design : The study single center , randomize , placebo control cross-over design . An open label one month run phase atorvastatin therapy utilized establish baseline endothelial function ensure tolerability atorvastatin . Brachial ultrasound determination FMD pulse arterial tonometry ( PAT ) utilize . Open label atorvastatin continue throughout study subject . Following baseline measurement endothelial function , patient randomize placebo escalating dos ER niacin treatment phase 3 month . At point , repeat measurement undertaken subject cross-over alternate therapy additional 3 month follow final measurement . The use different method endothelial function measurement allow comparison two . Subjects establish coronary atherosclerosis HDL &lt; 1.1 mmol/L , least one month post percutaneous coronary intervention ( PCI ) 3 month post coronary artery bypass graft ( CABG ) . Exclusion criterion include active gout , gallbladder peptic ulcer disease , change endothelial modulating drug within one month study initiation use niacin . The primary end-point study brachial artery flow-mediated vasodilation . The primary efficacy analysis comparison change FMD active ER niacin treatment compare baseline . The sample size base expect 2 % difference FMD ( SD 5 % ) , p &lt; 0.05 power 80 % . Significance : Despite reduction mortality current LDL lowering approach , morbidity mortality remain unacceptably high . HDL recently gain favor therapeutic target lower cardiovascular event rate . The current study evaluate effect HDL raise endothelial health , surrogate marker atherosclerosis activity .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Aged 1880 year Coronary artery disease HDL &gt; 1.10 ( men ) , &gt; 1.30 ( woman ) PCI within 30 day CABG within 90 day Symptomatic congestive heart failure ( CHF ) Uncontrolled hypertension Gout active gallbladder disease , liver disease peptic ulcer disease Diabetes ( Fasting blood sugar &gt; 7.0 hemoglobin A1c [ HbA1C ] &gt; 6.1 exclusionary ) Abnormalities complete blood count ( CBC ) , creatinine ALT Change endothelial modulating drug last month use niacin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>endothelial function</keyword>
	<keyword>HDL</keyword>
	<keyword>Niacin</keyword>
	<keyword>statin</keyword>
	<keyword>Stable Atherosclerotic Vascular Disease</keyword>
</DOC>